Manhattan Moment: The right prescription for drug safety

Published



Last month, the Supreme Court heard oral arguments for the most controversial and important business case on its winter docket, Wyeth v. Levine. Largely overlooked during the election, the case hinges on whether the FDA’s decision on what warnings should – or shouldn’t – be required on a prescription drug label “preempts” lawsuits in state courts alleging that drug companies failed to warn consumers of possible side effects.

A ruling in favor of FDA preemption would be a change for the better from the “sue anywhere, for anything” status quo.  Companies that provide the FDA – as Wyeth did – with truthful information about drug risks, which are then incorporated into the FDA-approved label, would be protected from “failure to warn” lawsuits.  Patients could still sue companies for withholding information from the FDA or for side-effects that weren’t listed on a drug’s label.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.